Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELAD in Acute Liver Failure
NCT01875874Phase 2Terminated
- Sponsor
- Vital Therapies, Inc.
- Start
- Oct 2014
- Primary completion
- Sep 2015
- Modality
- Cell Therapies, Device-based Delivery
- Countries
- 1
01
Overview
A Phase 2 trial of ELAD in acute liver failure (ALF), sponsored by Vital Therapies, Inc.. Started Oct 2014; status: terminated.
02
Drugs
ELAD
03
Conditions
acute liver failure (ALF)
Beyond the preview
Go deeper on NCT01875874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01875874.